New Cholesterol Drug, Alirocumab's (Praluent), High Price May Not Be Worth It: Study

WEDNESDAY, Jan. 2, 2019 — Despite being slashed by half in recent months, the price tag for advanced cholesterol-fighting drugs is still too high to make them cost-effective, a new analysis has concluded.
In March, the manufacturer of alirocumab…
Source: Topamax